Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 39
Filtrar
1.
Endocr Metab Immune Disord Drug Targets ; 21(10): 1775-1780, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-1562450

RESUMEN

In late 2019, SARS-COV-2 disease was firstly discovered in Wuhan, China and then it infected millions of people worldwide. Later, the World Health Organization (WHO) described COVID-19 as the first pandemic invading the world in the 21st century. The WHO has declared that the emerging infection will last long enough to force adjustments not only in people's lifestyles but also in the health care system. This amendment is expected to spread through many medical practices and specialties. A lot of diagnostic and therapeutic modalities have been proposed for COVID-19 management. The best strategy for the management of patients requires a multi-disciplinary team approach with correct decisions regarding the right timing of each modality of treatment. The participating multidisciplinary team for COVID-19 management includes six infectious diseases experts in Tanta University; one critical care management expert, an emergency medicine expert and two pharmacists in Tanta University. In this review, we reported our multi-disciplinary team experience with up to date literature guidance to propose a valid protocol for the management of COVID-19 patients in a limited resources setting.


Asunto(s)
Centros Médicos Académicos/métodos , COVID-19/prevención & control , Países en Desarrollo , Manejo de la Enfermedad , Recursos en Salud , Grupo de Atención al Paciente , Centros Médicos Académicos/economía , COVID-19/economía , COVID-19/epidemiología , Países en Desarrollo/economía , Egipto/epidemiología , Recursos en Salud/economía , Humanos , Grupo de Atención al Paciente/economía
6.
Glob Heart ; 16(1): 18, 2021 03 15.
Artículo en Inglés | MEDLINE | ID: covidwho-1175699

RESUMEN

The current pandemic of SARS-COV 2 infection (Covid-19) is challenging health systems and communities worldwide. At the individual level, the main biological system involved in Covid-19 is the respiratory system. Respiratory complications range from mild flu-like illness symptoms to a fatal respiratory distress syndrome or a severe and fulminant pneumonia. Critically, the presence of a pre-existing cardiovascular disease or its risk factors, such as hypertension or type II diabetes mellitus, increases the chance of having severe complications (including death) if infected by the virus. In addition, the infection can worsen an existing cardiovascular disease or precipitate new ones. This paper presents a contemporary review of cardiovascular complications of Covid-19. It also specifically examines the impact of the disease on those already vulnerable and on the poorly resourced health systems of Africa as well as the potential broader consequences on the socio-economic health of this region.


Asunto(s)
COVID-19/fisiopatología , Enfermedades Cardiovasculares/fisiopatología , Síndrome Coronario Agudo/economía , Síndrome Coronario Agudo/etiología , Síndrome Coronario Agudo/fisiopatología , África , Antimaláricos/efectos adversos , Arritmias Cardíacas/economía , Arritmias Cardíacas/etiología , Arritmias Cardíacas/fisiopatología , COVID-19/complicaciones , COVID-19/economía , Enfermedades Cardiovasculares/economía , Enfermedades Cardiovasculares/etiología , Cloroquina/efectos adversos , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/fisiopatología , Atención a la Salud/economía , Factores Económicos , Recesión Económica , Producto Interno Bruto , Recursos en Salud/economía , Recursos en Salud/provisión & distribución , Insuficiencia Cardíaca/economía , Insuficiencia Cardíaca/etiología , Insuficiencia Cardíaca/fisiopatología , Humanos , Hidroxicloroquina/efectos adversos , Inflamación , Isquemia Miocárdica/economía , Isquemia Miocárdica/etiología , Isquemia Miocárdica/fisiopatología , Miocarditis/economía , Miocarditis/etiología , Miocarditis/fisiopatología , SARS-CoV-2 , Síndrome Respiratorio Agudo Grave/complicaciones , Síndrome Respiratorio Agudo Grave/fisiopatología , Factores Socioeconómicos , Cardiomiopatía de Takotsubo/economía , Cardiomiopatía de Takotsubo/etiología , Cardiomiopatía de Takotsubo/fisiopatología
11.
MMWR Morb Mortal Wkly Rep ; 69(50): 1917-1921, 2020 Dec 18.
Artículo en Inglés | MEDLINE | ID: covidwho-1016446

RESUMEN

As school districts across the United States consider how to safely operate during the 2020-21 academic year, CDC recommends mitigation strategies that schools can adopt to reduce the risk for transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). To identify the resources and costs needed to implement school-based mitigation strategies and provide schools and jurisdictions with information to aid resource allocation, a microcosting methodology was employed to estimate costs in three categories: materials and consumables, additional custodial staff members, and potential additional transportation. National average estimates, using the national pre-kindergarten through grade 12 (preK-12) public enrollment of 50,685,567 students, range between a mean of $55 (materials and consumables only) to $442 (all three categories) per student. State-by-state estimates of additional funds needed as a percentage of fiscal year 2018 student expenditures (2) range from an additional 0.3% (materials and consumables only) to 7.1% (all three categories); however, only seven states had a maximum estimate above 4.2%. These estimates, although not exhaustive, highlight the level of resources needed to ensure that schools reopen and remain open in the safest possible manner and offer administrators at schools and school districts and other decision-makers the cost information necessary to budget and prioritize school resources during the COVID-19 pandemic.


Asunto(s)
COVID-19/prevención & control , Recursos en Salud/economía , Instituciones Académicas/economía , Adolescente , COVID-19/epidemiología , Centers for Disease Control and Prevention, U.S. , Niño , Preescolar , Costos y Análisis de Costo , Humanos , Instituciones Académicas/estadística & datos numéricos , Estados Unidos/epidemiología
12.
Med Leg J ; 89(1): 25-28, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: covidwho-983824

RESUMEN

The Covid-19 pandemic has created the opportunity for corruption to flourish in healthcare sectors around the world. Challenges include misuse and mismanagement of resources and corruption, which require scrutiny and attention. This article deals with such corruption during the pandemic, involving public procurement of goods and services for the treatment of diseases, falsification of public contracts and kickbacks, embezzlement of healthcare funds, opacity in governance, misuse of power, nepotism and favouritism in the management, petty corruption in the level of service, fraud and theft or embezzlement of medicines and medical devices.


Asunto(s)
COVID-19/economía , Atención a la Salud/economía , Atención a la Salud/organización & administración , Fraude , Recursos en Salud/economía , Robo , Gobierno , Humanos , Internacionalidad , Sector Público , Responsabilidad Social
13.
J Surg Res ; 260: 56-63, 2021 04.
Artículo en Inglés | MEDLINE | ID: covidwho-977146

RESUMEN

BACKGROUND: As the COVID-19 pandemic continues, there is a question of whether hospitals have adequate resources to manage patients. We aim to investigate global hospital bed (HB), acute care bed (ACB), and intensive care unit (ICU) bed capacity and determine any correlation between these hospital resources and COVID-19 mortality. METHOD: Cross-sectional study utilizing data from the World Health Organization (WHO) and other official organizations regarding global HB, ACB, ICU bed capacity, and confirmed COVID-19 cases/mortality. Descriptive statistics and linear regression were performed. RESULTS: A total of 183 countries were included with a mean of 307.1 HBs, 413.9 ACBs, and 8.73 ICU beds/100,000 population. High-income regions had the highest mean number of ICU beds (12.79) and HBs (402.32) per 100,000 population whereas upper middle-income regions had the highest mean number of ACBs (424.75) per 100,000. A weakly positive significant association was discovered between the number of ICU beds/100,000 population and COVID-19 mortality. No significant associations exist between the number of HBs or ACBs per 100,000 population and COVID-19 mortality. CONCLUSIONS: Global COVID-19 mortality rates are likely affected by multiple factors, including hospital resources, personnel, and bed capacity. Higher income regions of the world have greater ICU, acute care, and hospital bed capacities. Mandatory reporting of ICU, acute care, and hospital bed capacity/occupancy and information relating to coronavirus should be implemented. Adopting a tiered critical care approach and targeting the expansion of space, staff, and supplies may serve to maximize the quality of care during resurgences and future disasters.


Asunto(s)
COVID-19/terapia , Salud Global/estadística & datos numéricos , Recursos en Salud/estadística & datos numéricos , Capacidad de Camas en Hospitales/estadística & datos numéricos , Pandemias/prevención & control , COVID-19/mortalidad , Cuidados Críticos/economía , Cuidados Críticos/estadística & datos numéricos , Estudios Transversales , Carga Global de Enfermedades/estadística & datos numéricos , Salud Global/economía , Recursos en Salud/economía , Capacidad de Camas en Hospitales/economía , Humanos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Pandemias/estadística & datos numéricos
14.
J Hosp Med ; 15(12): 709-715, 2020 12.
Artículo en Inglés | MEDLINE | ID: covidwho-967311

RESUMEN

BACKGROUND: Academic medical centers have expanded their inpatient medicine services with advanced practice clinicians (APCs) or nonteaching hospitalists in response to patient volumes, residency work hour restrictions, and recently, COVID-19. Reports of clinical outcomes, cost, and resource utilization differ among inpatient team structures. OBJECTIVE: Directly compare outcomes among resident, APC, and solo hospitalist inpatient general medicine teams. DESIGN: Retrospective cohort study using multivariable analysis adjusted for time of admission, interhospital transfer, and comorbidities that compares clinical outcomes, cost, and resource utilization. SUBJECTS: Patients 18 years or older discharged from an inpatient medicine service between July 2015 and July 2018 (N = 12,716). MAIN MEASURES: Length of stay (LOS), 30-day readmission, inpatient mortality, normalized total direct cost, discharge time, and consultation utilization. KEY RESULTS: Resident teams admitted fewer patients at night (32.0%; P < .001) than did APC (49.5%) and hospitalist (48.6%) teams. APCs received nearly 4% more outside transfer patients (P = .015). Hospitalists discharged patients 26 minutes earlier than did residents (mean hours after midnight [95% CI], 14.58 [14.44-14.72] vs 15.02 [14.97-15.08]). Adjusted consult utilization was 15% higher for APCs (adjusted mean consults per admission [95% CI], 1.00 [0.96-1.03]) and 8% higher for residents (0.93 [0.90-0.95]) than it was for hospitalists (0.85 [0.80-0.90]). No differences in LOS, readmission, mortality, or cost were observed between the teams. CONCLUSION: We observed similar costs, LOS, 30-day readmission, and mortality among hospitalist, APC, and resident teams. Our results suggest clinical outcomes are not significantly affected by team structure. The addition of APC or hospitalist teams represent safe and effective alternatives to traditional inpatient resident teams.


Asunto(s)
Centros Médicos Académicos , Recursos en Salud/economía , Médicos Hospitalarios/economía , Medicina Interna , Internado y Residencia , Evaluación del Resultado de la Atención al Paciente , Femenino , Humanos , Medicina Interna/economía , Medicina Interna/educación , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Readmisión del Paciente , Calidad de la Atención de Salud/estadística & datos numéricos , Estudios Retrospectivos
15.
J Clin Gastroenterol ; 54(10): 833-840, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-963399

RESUMEN

Performance of endoscopic procedures is associated with a risk of infection from COVID-19. This risk can be reduced by the use of personal protective equipment (PPE). However, shortage of PPE has emerged as an important issue in managing the pandemic in both traditionally high and low-resource areas. A group of clinicians and researchers from thirteen countries representing low, middle, and high-income areas has developed recommendations for optimal utilization of PPE before, during, and after gastrointestinal endoscopy with particular reference to low-resource situations. We determined that there is limited flexibility with regard to the utilization of PPE between ideal and low-resource settings. Some compromises are possible, especially with regard to PPE use, during endoscopic procedures. We have, therefore, also stressed the need to prevent transmission of COVID-19 by measures other than PPE and to conserve PPE by reduction of patient volume, limiting procedures to urgent or emergent, and reducing the number of staff and trainees involved in procedures. This guidance aims to optimize utilization of PPE and protection of health care providers.


Asunto(s)
Infecciones por Coronavirus/prevención & control , Endoscopía Gastrointestinal/economía , Recursos en Salud/economía , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/prevención & control , Pandemias/prevención & control , Equipo de Protección Personal/normas , Neumonía Viral/prevención & control , Guías de Práctica Clínica como Asunto , COVID-19 , Infecciones por Coronavirus/epidemiología , Endoscopía Gastrointestinal/estadística & datos numéricos , Femenino , Gastroenterología/normas , Salud Global , Humanos , Control de Infecciones/organización & administración , Internacionalidad , Masculino , Salud Laboral/estadística & datos numéricos , Pandemias/estadística & datos numéricos , Equipo de Protección Personal/estadística & datos numéricos , Neumonía Viral/epidemiología , Pobreza , Sociedades Médicas
16.
Popul Health Manag ; 23(5): 361-367, 2020 10.
Artículo en Inglés | MEDLINE | ID: covidwho-936312

RESUMEN

Technology has played an important role in responding to the novel coronavirus (SARS-CoV-2) and subsequent COVID-19 pandemic. The virus's blend of lethality and transmissibility have challenged officials and exposed critical limitations of the traditional public health apparatus. However, throughout this pandemic, technology has answered the call for a new form of public health that illustrates opportunities for enhanced agility, scale, and responsiveness. The authors share the Microsoft perspective and illustrate how technology has helped transform the public health landscape with new and refined capabilities - the efficacy and impact of which will be determined by history. Technologies like chatbot and virtualized patient care offer a mechanism to triage and distribute care at scale. Artificial intelligence and high-performance computing have accelerated research into understanding the virus and developing targeted therapeutics to treat infection and prevent transmission. New mobile contact tracing protocols that preserve patient privacy and civil liberties were developed in response to public concerns, creating new opportunities for privacy-sensitive technologies that aid efforts to prevent and control outbreaks. While much progress is still needed, the COVID-19 pandemic has highlighted technology's importance to public health security and pandemic preparedness. Future multi-stakeholder collaborations, including those with technology organizations, are needed to facilitate progress in overcoming the current pandemic, setting the stage for improved pandemic preparedness in the future. As lessons are assessed from the current pandemic, public officials should consider technology's role and continue to seek opportunities to supplement and improve on traditional approaches.


Asunto(s)
Tecnología Biomédica/métodos , Infecciones por Coronavirus/prevención & control , Control de Infecciones/organización & administración , Pandemias/prevención & control , Neumonía Viral/prevención & control , Salud Pública/normas , Terapia de Exposición Mediante Realidad Virtual/métodos , Tecnología Biomédica/estadística & datos numéricos , COVID-19 , Control de Enfermedades Transmisibles/organización & administración , Infecciones por Coronavirus/epidemiología , Femenino , Recursos en Salud/economía , Humanos , Masculino , Pandemias/estadística & datos numéricos , Neumonía Viral/epidemiología , Gestión de la Salud Poblacional , Medición de Riesgo , Rol , Programas Informáticos/estadística & datos numéricos , Estados Unidos , Terapia de Exposición Mediante Realidad Virtual/estadística & datos numéricos
17.
Malar J ; 19(1): 411, 2020 Nov 16.
Artículo en Inglés | MEDLINE | ID: covidwho-927504

RESUMEN

The global COVID-19 pandemic has been affecting the maintenance of various disease control programmes, including malaria. In some malaria-endemic countries, funding and personnel reallocations were executed from malaria control programmes to support COVID-19 response efforts, resulting mainly in interruptions of disease control activities and reduced capabilities of health system. While it is principal to drive national budget rearrangements during the pandemic, the long-standing malaria control programmes should not be left behind in order to sustain the achievements from the previous years. With different levels of intensity, many countries have been struggling to improve the health system resilience and to mitigate the unavoidable stagnation of malaria control programmes. Current opinion emphasized the impacts of budget reprioritization on malaria-related resources during COVID-19 pandemic in malaria endemic countries in Africa and Southeast Asia, and feasible attempts that can be taken to lessen these impacts.


Asunto(s)
Presupuestos/tendencias , Infecciones por Coronavirus/economía , Enfermedades Endémicas/economía , Recursos en Salud/economía , Malaria/economía , Pandemias/economía , Neumonía Viral/economía , África , Asia Sudoriental , Presupuestos/estadística & datos numéricos , COVID-19 , Infecciones por Coronavirus/prevención & control , Enfermedades Endémicas/prevención & control , Recursos en Salud/tendencias , Humanos , Malaria/prevención & control , Control de Mosquitos/economía , Control de Mosquitos/tendencias , Pandemias/prevención & control , Neumonía Viral/prevención & control
18.
Geriatr Gerontol Int ; 20(12): 1112-1119, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: covidwho-901048

RESUMEN

Since the end of 2019, a life-threatening infectious disease (coronavirus disease 2019: COVID-19) has spread globally, and numerous victims have been reported. In particular, older persons tend to suffer more severely when infected with a novel coronavirus (SARS-CoV-2) and have higher case mortality rates; additionally, outbreaks frequently occur in hospitals and long-term care facilities where most of the residents are older persons. Unfortunately, it has been stated that the COVID-19 pandemic has caused a medical collapse in some countries, resulting in the depletion of medical resources, such as ventilators, and triage based on chronological age. Furthermore, as some COVID-19 cases show a rapid deterioration of clinical symptoms and accordingly, the medical and long-term care staff cannot always confirm the patient's values and wishes in time, we are very concerned as to whether older patients are receiving the medical and long-term care services that they wish for. It was once again recognized that it is vital to implement advance care planning as early as possible before suffering from COVID-19. To this end, in August 2020, the Japan Geriatrics Society announced ethical recommendations for medical and long-term care for older persons and emphasized the importance of conducting advance care planning at earlier stages. Geriatr Gerontol Int 2020; 20: 1112-1119.


Asunto(s)
Planificación Anticipada de Atención , COVID-19/terapia , Cuidados a Largo Plazo/ética , Planificación Anticipada de Atención/ética , Anciano , Anciano de 80 o más Años , COVID-19/epidemiología , COVID-19/mortalidad , COVID-19/prevención & control , Consenso , Toma de Decisiones/ética , Geriatría/normas , Recursos en Salud/economía , Humanos , Japón , Pandemias/ética , Triaje/ética
19.
Nature ; 580(7805): 578-580, 2020 04.
Artículo en Inglés | MEDLINE | ID: covidwho-827033
20.
Transfusion ; 60(12): 2828-2833, 2020 12.
Artículo en Inglés | MEDLINE | ID: covidwho-808782

RESUMEN

BACKGROUND: Arkansas is a rural state of 3 million people. It is ranked fifth for poverty nationally. The first case of coronavirus disease 2019 (COVID-19) in Arkansas occurred on 11 March 2020. Since then, approximately 8% of all Arkansans have tested positive. Given the resource limitations of Arkansas, COVID-19 convalescent plasma (CCP) was explored as a potentially lifesaving, therapeutic option. Therefore, the Arkansas Initiative for Convalescent Plasma was developed to ensure that every Arkansan has access to this therapy. STUDY DESIGN AND METHOD: This brief report describes the statewide collaborative response from hospitals, blood collectors, and the Arkansas Department of Health (ADH) to ensure that CCP was available in a resource-limited state. RESULTS: Early contact tracing by ADH identified individuals who had come into contact with "patient zero" in early March. Within the first week, 32 patients tested positive for COVID-19. The first set of CCP collections occurred on 9 April 2020. Donors had to be triaged carefully in the initial period, as many had recently resolved their symptoms. From our first collections, with appropriate resource and inventory management, we collected sufficient CCP to provide the requested number of units for every patient treated with CCP in Arkansas. CONCLUSIONS: The Arkansas Initiative, a statewide effort to ensure CCP for every patient in a resource-limited state, required careful coordination among key players. Collaboration and resource management was crucial to meet the demand of CCP products and potentially save lives.


Asunto(s)
COVID-19/terapia , Recursos en Salud/provisión & distribución , Accesibilidad a los Servicios de Salud/organización & administración , Pandemias , Asignación de Recursos/organización & administración , SARS-CoV-2/inmunología , Anticuerpos Antivirales/sangre , Arkansas/epidemiología , Bancos de Sangre/economía , Bancos de Sangre/organización & administración , Donantes de Sangre/provisión & distribución , COVID-19/sangre , COVID-19/economía , COVID-19/epidemiología , Planificación en Salud Comunitaria/economía , Planificación en Salud Comunitaria/organización & administración , Trazado de Contacto , Convalecencia , Recursos en Salud/economía , Accesibilidad a los Servicios de Salud/economía , Humanos , Inmunización Pasiva , Colaboración Intersectorial , Pobreza , Asignación de Recursos/economía , Población Rural , Sueroterapia para COVID-19
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA